Fulton Breakefield Broenniman LLC Has $18.16 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV)

Fulton Breakefield Broenniman LLC cut its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 3.4% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 86,662 shares of the company's stock after selling 3,049 shares during the quarter. AbbVie makes up approximately 1.3% of Fulton Breakefield Broenniman LLC's holdings, making the stock its 22nd largest holding. Fulton Breakefield Broenniman LLC's holdings in AbbVie were worth $18,157,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of ABBV. EnRich Financial Partners LLC lifted its stake in shares of AbbVie by 196.4% in the fourth quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock valued at $29,000 after buying an additional 110 shares during the period. Abound Financial LLC acquired a new stake in shares of AbbVie in the 1st quarter valued at approximately $30,000. Prudent Man Investment Management Inc. bought a new position in AbbVie during the fourth quarter worth $32,000. Siemens Fonds Invest GmbH increased its holdings in shares of AbbVie by 197.6% during the fourth quarter. Siemens Fonds Invest GmbH now owns 179,440 shares of the company's stock worth $32,000 after purchasing an additional 119,141 shares during the period. Finally, Pinney & Scofield Inc. acquired a new stake in AbbVie in the fourth quarter valued at about $36,000. Institutional investors and hedge funds own 70.23% of the company's stock.

Analysts Set New Price Targets

ABBV has been the subject of a number of research analyst reports. Wall Street Zen lowered AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Erste Group Bank raised AbbVie to a "strong-buy" rating in a research note on Monday, March 17th. Evercore ISI increased their price target on shares of AbbVie from $204.00 to $205.00 and gave the company an "outperform" rating in a report on Monday, April 28th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $194.00 price objective on shares of AbbVie in a research note on Tuesday, April 8th. Finally, Guggenheim increased their price target on AbbVie from $214.00 to $216.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Eight investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $211.29.

AbbVie Trading Down 1.2%

NYSE:ABBV traded down $2.28 during trading hours on Monday, reaching $190.17. 927,095 shares of the company were exchanged, compared to its average volume of 6,290,475. The firm has a market cap of $335.91 billion, a price-to-earnings ratio of 80.94, a PEG ratio of 1.28 and a beta of 0.48. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.76 and a quick ratio of 0.64. AbbVie Inc. has a 52-week low of $163.81 and a 52-week high of $218.66. The stock has a 50 day simple moving average of $187.01 and a 200 day simple moving average of $189.11.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.40 by $0.06. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The firm had revenue of $13.34 billion for the quarter, compared to analysts' expectations of $12.91 billion. During the same period last year, the business posted $2.31 earnings per share. The firm's revenue for the quarter was up 8.4% on a year-over-year basis. As a group, analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be paid a $1.64 dividend. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $6.56 annualized dividend and a yield of 3.45%. AbbVie's dividend payout ratio is presently 279.15%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.